OM-85 attenuates high-fat diet-induced obesity, insulin resistance, gut dysbiosis and nonalcoholic steatohepatitis in a murine model
Open Access
- 2 December 2024
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 181, 117710
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (1R16GM145586)
- OM Pharma
This publication has 53 references indexed in Scilit:
- Long-term hexavalent chromium exposure facilitates colorectal cancer in mice associated with changes in gut microbiota compositionFood and Chemical Toxicology, 2020
- Immune tolerance attenuates gut dysbiosis, dysregulated uterine gene expression and high-fat diet potentiated preterm birth in miceAmerican Journal of Obstetrics and Gynecology, 2019
- Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysisInternational Immunopharmacology, 2018
- Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitisMetabolism, 2016
- Immune Regulation of Metabolic Homeostasis in Health and DiseaseCell, 2015
- A Mouse Model of Diet-Induced Obesity and Insulin Resistance2011
- Overweight, Obesity, and DepressionArchives of General Psychiatry, 2010
- OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic reviewWorld Journal of Pediatrics, 2010
- Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer DiseaseArchives of Neurology, 2005
- Overweight and Obesity as Determinants of Cardiovascular RiskArchives of internal medicine (1960), 2002